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Abstract 
Introduction: Patients with disorders/differences of sex differentiation/development (DSD) 
are exposed to physical and mental suffering. The aim of the study was to assess the 
following: the mental health status and the risk of mental problems in adult DSD patients, 
their dependence on therapeutic procedures, and to identify groups of disorders that require 
particular psychological support. 
Material and methods: The study involved 59 patients with DSD (gonadal dysgenesis — 
GD, androgen insensitivity syndrome — AIS, 5-alpha reductase deficiency, ovotestis), and 
with the Y chromosome in the karyotype, aged 16–65 years. All completed the General 
Health Questionnaire (GHQ-28) for the assessment of their mental health status. Raw results 
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were converted into sten scores using norms for the Polish adult population to assess the risk 
of mental problems. 
Results: A high risk of mental problems was identified in 24% of individuals (26% men, 21% 
women). Women, when compared with men, displayed a significantly higher mean level of 
anxiety and insomnia (7.3 vs. 4.6 scores) and somatic symptoms (7.4 vs. 5.5), and worse 
general mental health status (25.6 vs. 18.8). The most disturbing symptoms were observed 
among patients with complete and partial AIS, and complete GD (general mental health 
status: 39.5, 24.3, and 24.2, respectively), women lacking a vagina (27.2), and without an 
enlarged clitoris (27.5). Patients after genital surgery had significantly fewer somatic 
symptoms (5.4 vs. 7.8; p < 0.05) and better general mental health status in comparison to 
those without surgery (20.1 vs. 24.9; p < 0.05). No significant differences were observed 
between patients using hormone replacement therapy and those who were not. 
Conclusions: The individuals with DSD and Y chromosome in the karyotype have increased 
risk of developing mental problems in comparison to the general Polish population. The risk 
factors seem to be as follows: female gender, the lack of a vagina, the lack of virilisation (no 
enlarged clitoris), and no genital operations performed. In some cases, sex hormone 
replacement therapy may be also the risk of mental problems. Particularly vulnerable groups 
are CAIS, PAIS, and CGD. The psychological support and an individual approach to 
particular needs of these patients is necessary. 
 
Key words: mental health; somatic symptoms; hypogonadism; ambiguous genitalia; 
hormonal substitution; genital operations 
 
Introduction  
Human sexual differentiation is a complex process that takes place during the foetal 
period of life. Its disruption results in the occurrence of disorders/differences of sex 
differentiation/development (DSD). This term is used to describe a group of congenital 
defects manifested by abnormal gonads and/or genital anatomy. Disorders of sex 
differentiation are relatively rare, with a frequency of about 1:4500–5000 births [1, 2], but 
they are the cause of many diagnostic and therapeutic problems, as well as psychological 
problems of the patient and their family. Significantly more problems are observed in DSD 
patients with the Y chromosome, or its part, in the karyotype. The reason may be various 
congenital defects in male differentiation. One of them is a disorder in testicular 
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differentiation such as: complete dysgenesis, where there are only streaks of connective tissue 
on both sides, partial dysgenesis, where testes are underdeveloped on both sides, asymmetric 
dysgenesis, where testis is on one side and connective tissue on the other, and the 
differentiation of the gonad into testis and ovary (ovotestis) in one or both sides. Other 
congenital defects such as androgen biosynthesis disorders, i.e. deficiency in 5-alpha 
reductase activity, an enzyme converting testosterone to the more active dihydrotestosterone, 
or insensitivity to androgens, where androgen activity can be absent in all or only some 
tissues, can also be the reason for DSD in individuals with Y chromosome. Usually serious 
abnormalities in the development of genitals are an indication for multistage genital surgery. 
Disorders that require many reconstructive operations cause greater physical and mental 
suffering [3, 4]. Moreover, DSD patients with Y chromosome are at high risk of germ cell 
neoplastic lesions in the gonads, which is often an indication for gonadectomy [5]. 
Nordenskjöld et al. showed that psychological wellbeing is influenced by the type and 
severity of DSD, and this influence is observed in the long term [3].  
Puberty is the most difficult period from the psychological point of view, when sexuality, 
sexual identity, and gender role, as well as sexual orientation, become highly important [6, 7]. 
In many cases a diagnosis of DSD leads to anger, shame, and depression. A study of 86 
patients with DSD aged 8–12 years from Germany, Austria, and Switzerland showed that 
pubertal children with these disorders tend to experience a worse quality of life [8]. A 
significant reduction in self-esteem, well-being, and functioning at school was observed. 
Similarly, although around half (54.9%) of 51 children and adolescents with DSD studied in 
Turkey were not found to have a mental illness, the remaining 45.1% displayed depression, 
anxiety disorders, concentration disorders, and hyperactivity [9].  
A significant problem faced by people with DSD is the lack of acceptance of their body 
dissimilarity and the associated shame, which typically leads to the avoidance of sexual 
contact and social exclusion. In particular, young people with DSD rarely develop close 
relationships with their peers [10, 11]. Many teenagers with DSD experience puberty later 
than their peers or fail to spontaneously mature without sex hormone substitution. Differences 
in physical development and appearance, such as lack of breast development, lack of 
menstruation, lack of voice mutation, and lack of sexual hair, can cause stigmatisation, which 
significantly limits social relations. 
The occurrence and severity of mental disorders can also be influenced by clinical 
management [12–15]. Firstly, the patient’s right to intimacy is of great importance. This 
should be considered during examination, but also access to medical records, which often 
4 
 
contain genital images, should be limited. The best possible mental state can be ensured by 
providing proper information on methods and consequences of the therapy, as well as 
providing psychological support adjusted to the age of the patient at each stage of treatment. 
According to the consensus of the American Lawson Wilkins Pediatric Endocrine Society 
(LWPES) and the European Society for Paediatric Endocrinology (ESPE), psychological 
support should be made available to both the patient with DSD and the family. The necessity 
of psychological support was even more clearly emphasised in the consensus update in 2016 
[16, 17]. Disorders of sex differentiation support groups may also be an important source of 
help. 
 The aim of the study was to assess the mental health status and the risk of mental 
disorders in adult patients with DSD and Y chromosome in the Polish population, as well as 
the dependence of mental problems on therapeutic procedures, and to identify groups of 
disorders requiring particular psychological support. 
 
Material and methods 
 The study was conducted among patients of the Endocrine Outpatients’ Clinic of the 
Children’s Memorial Health Institute in Warsaw and the Department of Andrology and 
Reproductive Endocrinology of the Medical University in Lodz, Poland. The study was 
approved by the Bioethics Committee of the Medical University in Lodz (no. RNN / 28/ 10 / 
KE). 
 
Study group  
The study inclusion criteria were the following: diagnosis of DSD, Y chromosome in 
the karyotype, age ≥ 16 years, and a recorded sex: either female (women) or male (men). 
Patients were recruited among persons in the intellectual norm (never diagnosed as 
intellectually disabled). About 72% had medium or higher education; however, the median 
age of participants was young, and several persons were still in the course of education.  
The study included 59 patients (28 women and 31 men) aged 16–65 years (median 26 
years). Among them four people reported gender dysphoria. The largest group was between 
20 and 30 years old — 28 patients (47.5%), followed by the group under 20 years old — 18 
patients (30.5%), the next largest age group were patients over 40 years old — eight patients 
(13.5%), and the least numerous group was from 30 to 40 years old — five patients (8.5%). 
The subjects were patients with disorders such as complete (CGD), partial (PGD), and 
asymmetric gonadal dysgenesis (AGD), ovotestis, complete (CAIS) and partial androgen 
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insensitivity syndrome (PAIS), and 5-alpha reductase deficiency (5-ARD). All presented 
disorders of male external genitalia differentiation. 
Data regarding diagnosis, medical history, and applied therapies were obtained from 
available medical documentation. Each of the subjects underwent a medical examination. 
The study group was divided by: 1) gender, 2) diagnosis, 3) clinical picture (disorders 
of genital development: men — micropenis (length < 7.5 cm), hypospadias; women — 
virilisation mainly manifested as an enlarged clitoris), and 4) treatment methods (substitution 
with sex hormones, genital surgery). All examined men had the micropenis, and all except 
one patient presented severe hypospadias (perineal or scrotal). Among those who had 
undergone genital surgery procedures (34 subjects, 58% of all) 29 were men (94% of all men) 
and five were women (21% of all women). Hormonal substitution was received by 36 subjects 
(61% of all): 26 women (93% of all women) and 10 men (32% of all men). All subjects were 
under the care of an endocrinologist and claimed that they were taking the medicine as it had 
been prescribed. Some patients were diagnosed with hypertension, type 2 diabetes, 
dyslipidaemia, osteopaenia, autoimmune disease, and gastric and eye problems. None of the 
diseases was serious. 
The general characteristics of the subjects are presented in Table 1. 
 
Evaluation of mental health status  
The subjects completed the General Health Questionnaire (GHQ-28), which is used to 
assess mental health status in adults. The questionnaire consists of 28 questions to assess the 
severity of: 1) somatic symptoms, 2) anxiety and insomnia, 3) disorders of daily functioning, 
and 4) symptoms of depression. The respondents chose one of four possible answers: better 
than usual, as usual, worse than usual, much worse than usual. The results were scored using 
a Likert scale (0–1–2–3). Each scale can be scored separately, giving a total score between 0 
and 21 points for each scale, with a higher score indicating more disturbing symptoms. In 
addition, the sum of all points obtained on all four scales can be used as an assessment of the 
general mental health status, with a possible final result ranging from 0 to 84 points.  
In order to determine statistically significant differences of mean test results, comparisons 
were made in the following groups: 1) gender, 2) diagnosis, 3) clinical picture, and 4) 
treatment. In this way it was possible to determine what parameters of GHQ-28 differ in those 
groups. In Table 2, letters a or b are marked in the compared pairs (a-a, a1-a1, a2-a2, b-b) 
statistically significant at the level of p < 0.05 and p < 0.01.  
6 
 
The raw results for each scale and for the sum of the points obtained were converted into 
sten scores (from 1 to 10) using the norms for the Polish adult population included in the test 
manual [18]. The mean sten score in the nationwide population is 5.5 with a standard 
deviation of 2. The risk of mental problems was determined to be high when the number of 
the sten scores was higher than that of the nationwide population.  
 
Statistical analysis 
Statistical analyses were performed using Statistica 10 software (StatSoft, Poland). 
The normality of the distribution of raw results was tested by the Shapiro-Wilk test. When 
comparing two independent samples, Student’s t-test was used for the analysis of data with a 
normal distribution, while the Mann-Whitney U-test was used for abnormal distribution. 
Comparisons of more than two independent samples were carried out using ANOVA tests: 
ANOVA one-way for results with normal distribution, and the Kruskal-Wallis H-test for those 
with a non-normal distribution. The assumed level for all applied statistical tests was p < 0.05. 
 
Results  
The mean results of the GHQ-28 for the whole group and according to recorded sex, 
diagnosis, clinical picture, and treatment options are presented in Table II. They show that 
DSD women compared with DSD men displayed a significantly higher average level of 
anxiety and insomnia (7.3 vs. 4.6 scores), more somatic symptoms (7.4 vs. 5.5 scores), and 
worse general mental health status (25.6 vs. 18.8 scores).  
The most disturbing symptoms were observed especially among patients with PAIS and 
CGD: the mean overall score of the general mental health status was higher in these groups 
than in the whole group (24.3 and 24.2 vs. 22.1 scores) but not significantly. The result of the 
general mental health status in the CAIS patients was particularly high (39.5 scores); 
however, the group was very small, which does not allow us to draw reliable conclusions. 
Nevertheless, poor general mental health was also presented by women without a vagina and 
without virilisation, symptoms typical for CAIS women. A comparison of the mean test 
results with regard to the diagnosis revealed statistically significant differences between 
groups only in the mean level of somatic symptoms. 
Taking into account the clinical picture, the most disturbing general mental health status 
was presented by women lacking a vagina (27.2 scores) and without an enlarged clitoris 
(without virilisation) (27.5 scores). The majority of disorders in daily functioning were 
reported by women without a vagina (8.4 scores). Anxiety and insomnia were mostly 
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observed in women with a vagina (7.5 scores) and women without virilisation (8.0 scores). 
The least disturbing symptoms (general mental health status) were found among the men with 
micropenis (18.8 scores) and hypospadias (18.6 scores). Statistically significantly higher level 
of functional disorders was shown by the women without a vagina and the women with 
virilisation than the men with micropenis (8.4 vs. 6.5 and 7.8 vs. 6.5 scores, respectively; p < 
0.05). Disorders of sex differentiation women without virilisation presented significantly 
worse general mental health status than DSD men with micropenis (27.5 vs. 18.8 scores; p < 
0.01) and reported also the significantly higher levels of anxiety and insomnia (8.0 vs. 4.6 
scores; p < 0.05).  
Analysis of the examined groups depending on the applied therapies showed that patients 
after genital surgery had significantly fewer somatic symptoms (5.4 vs. 7.8; p < 0.05) and 
better general mental health status in comparison to the patients without surgery (20.1 vs. 
24.9; p < 0.05). No significant differences were observed between patients using hormone 
replacement therapy and those who were not; however, patients with hormonal substitution 
presented worse general mental health status (23.6 vs. 19.6). 
An analysis of the risk of mental problems with regard to the recorded sex, diagnosis, 
clinical picture, and treatment in comparison to the Polish nationwide population is presented 
in Table 3. A high risk (7–10 stens), i.e. higher than in the nationwide population, was found 
in 14 subjects (24%), while a moderate (5–6 stens), i.e. similar to that observed in the 
nationwide population, in 27 subjects (46%). With regard to the recorded sex, it was found 
that 26% of men and 21% of women had higher risk of mental problems than the general 
Polish population.  
The analysis of the results with regard to the diagnosis showed that the highest number of 
DSD patients had low or medium risk of mental problems. High risk was found in 25% of 
patients with PGD and AGD, as well as in 50% of the subjects from the smallest groups: 
CAIS and “other”.  
Regarding the clinical picture, the risk of mental problems was most frequently found to 
be the same as in the general Polish population. High risk was identified in 25% of DSD 
women without virilisation and 26% of DSD men with micropenis. With regard to the applied 
treatment, it was found that most frequently the patients after genital surgery (26%) and the 
patients with hormonal therapy (25%) had high risk of mental problems, i.e. higher than the 
general Polish population. 
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Discussion 
In the presented study, every fourth respondent was found to demonstrate a higher risk 
of mental problems than the nationwide Polish population. Of the four types of symptoms 
examined in GHQ-28, the most disturbing were the daily functioning disorders and somatic 
symptoms. The high risk of mental problems means the presence of suicidal thoughts and risk 
of their realisation, higher than in the general Polish population. For comparison, in the dsd-
LIFE study conducted in 14 centres in six European countries, including two centres in 
Poland, the mental health status was assessed in 1022 persons with various forms of DSD 
[19]. Almost 20% of participants sometimes or often had suicidal thoughts, almost 7% had 
attempted suicide, and 27% reported chronic psychiatric problems, while in the general 
European population the suicidal thoughts rate is 9.2% and the suicidal attempt rate is 2.7%. 
Mental problems were observed predominantly among men with Klinefelter syndrome, but 
also in men with 46,XY DSD [19, 20]. Johannsen et al. [4] also reported an increased 
incidence of mental problems in adult DSD patients. In turn, over half (55%) of a group of 
children with various causes of DSD studied in Turkey were found to have no psychiatric 
symptoms, but 12% had mood disorders and 6% had anxiety disorders [8]. In contrast, a study 
conducted in China failed to find any significant differences in the social functioning of 
persons with DSD compared to the general population [22]. However, the authors indicate 
that those with DSD tended to display a poorer mental health status compared to the general 
population.  
The risk of mental problems may depend on the culture and social group, in which DSD 
persons live. Different social and cultural groups have variable expectations and definitions of 
masculinity and femininity, which define appropriate behaviours, personality attributes, and 
social roles. The way DSD is viewed and managed in different cultures varies widely. Warne 
and Raza [23] suggest that DSD is such a complex condition that even well-educated people 
find it difficult to understand. When families are very poor and lacking in basic education, and 
the health system is starved of resources, traditional beliefs, folk remedies, and prejudice 
combine to make the lives of children and adults with DSD extremely difficult. 
Stigmatisation, isolation, and withdrawal from social interaction may be stressful and may 
lead to mental problems [24].  
It might be supposed also that the level of intelligence is associated with the level of 
potential psychic illness risk. However, Barchmann and Kinze [25] found out that only 6% of 
the patients from a child psychiatric population had IQ over 120. The authors observed that 
with higher intelligence are found better performances of concentration, more reflexive style 
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of study, better school notes, and more favourable motor capabilities, but also less 
pronounced signs of anxiety and neuroticism, as well as a poorer social adaptation and less 
favourable effects of treatment. In our study most of the participants had medium or higher 
education and nobody was diagnosed as mentally retarded; however, we did not assess the IQ 
of the DSD patients. 
Disorders of sex differentiation are usually considered as quite severe diseases, with many 
health complications such as hypogonadism, infertility, poor sexual function, and possibly 
other disorders not related to DSD. All of these problems have been confirmed by dsd-LIFE 
study [20, 26–28]. However, the dsd-LIFE study revealed that fair to very good general health 
was reported by 91.4% of DSD subjects, and only 8.6% reported bad/very bad general health, 
while in the general European population it is, respectively, 94.0% and 6.0%. Longstanding 
health issues other than DSD and feeling limited in daily life were reported in 51.0% and 
38.6%, respectively (controls 24.5% and 13.8%). A disorder other than DSD was present in 
84.3%, while in controls it was 24.6%. In all DSD subgroups Klinefelter and Turner patients 
reported comorbidities the most frequently (94.5% and 87.1%, respectively), while 46,XY 
DSD patients less often (75%). There are not many studies showing a comparison of mental 
health status between DSD and other severe diseases. For example, Warne et al. [29] argue 
that no significant differences exist between people with DSD and age-matched adults with 
insulin dependent diabetes mellitus in terms of physical and mental health or the occurrence 
of depression or anxiety symptoms. 
In the presented study, worse results were obtained by the women than by the men. The 
women with DSD had significantly more somatic symptoms, more symptoms of anxiety and 
insomnia, and their overall mental health was worse than that of the men with DSD. These 
findings indicate that DSD women may require psychological and psychiatric support more 
often than DSD men. Similar observations were made in a Brazilian study on the quality of 
life of adults with DSD [30]. In addition, a study conducted in Italy found that almost one 
third of women with DSD declared using psychiatric drugs [21], which is higher than in the 
general population, in which psychiatric treatment is used by 12% of Italian women. 
Wisniewski and Mazur [31] claim that all 46,XY DSD conditions are under-studied. They 
suggest that in order to improve the quality of life of DSD persons more attention should be 
devoted to the study of their mental and general health, cognitive abilities, fertility, and sexual 
function.  
Among the subjects examined in the presented study, the worst overall mental health 
status was demonstrated in the patients with CAIS, PAIS, and CGD. The women with CAIS 
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had the highest severity of symptoms in all scales of the GHQ-28. These women are 
characterised by a male karyotype (46,XY), female gender identity, female body proportions, 
female external genitalia, lack of vaginal development (short, blindly ended), lack of or very 
weak pubic hair, presence of testicles in the abdomen or the upper part of inguinal canal, and 
infertility. Although CAIS does not provide symptoms at first glance, patients with this 
disorder may experience reduced mood and low self-esteem, and reveal uncertainty in sexual 
contact because of the awareness of having a male karyotype and testicles [32]. In another 
study, almost every woman with CAIS admitted that at some point in her life she needed 
psychological help [33]. Minto et al. [34] indicate that infertility, in particular, causes mental 
problems in CAIS women, because they feel worse than other women. 
Although none of the diagnostic groups in the present study displayed psychiatric 
disorders as serious as those reported by the women with CAIS, other studies have noted 
much more serious psychological consequences in the case of PAIS. Both men and women 
with this diagnosis have reported mental problems, suicidal tendencies, and suicide attempts 
[32, 35, 36]. In patients with 5-ARD, increased mental distress and suicidal thoughts were 
also observed, especially in patients raised as women [32]. 
In the presented study, more than one half of the subjects (58%) had undergone at least 
one genital surgery procedure: almost all men (94%) and every fifth woman (21%). These 
procedures are used less frequently in Poland than in other countries. For comparison, a 
German study by Jürgensen et al. [37] found 90% of DSD adolescents and 87% of DSD 
adults to have undergone at least one operation associated with DSD. Patients without 
surgical correction of reproductive organs reported more worrying somatic symptoms, and 
their overall mental health status was worse than patients after surgery, demonstrating the 
positive effect of plastic genital surgery on the mental health of persons with DSD. Other 
studies also have shown that well-performed corrective surgery has a positive effect on mental 
health status [38]. However, in a German study, where patients with 46,XY DSD were 
examined after genital surgery, almost half (47%) were not satisfied with the effects of the 
operation, and 37% reported dissatisfaction with the quality of sexual life. Therefore, in recent 
years, many specialists suggest limiting the number of surgical operations performed on 
genital organs in DSD patients, especially in younger children [39]. It might be suggested that 
with the increasing number of surgical operations the mental health status is becoming worse. 
Unfortunately, we were not able to check this in our group of DSD patients because of the 
missing medical documentation, especially from childhood.   
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It has been shown also that well-planned and conducted hormonal replacement therapy 
may have a positive influence on well-being [38]. However, in our study, DSD patients using 
substitution with sex hormones presented the worse general mental health status in 
comparison to those who were not, but not significantly. Patients with a high risk of mental 
problems were identified more frequently in the group using sex hormone therapy. In other 
studies, it was demonstrated that the lack of gonads, which is associated with a deficiency of 
sex steroids (hypogonadism) and hence a lack of secondary sexual characteristic development 
requiring hormonal substitution, may cause not only low self-esteem and shame, but also 
negatively affect the sexual life of adult patients [39]. The development of mental health 
problems has been attributed to improperly carried out hormonal substitution: poorly selected 
hormonal preparation, incorrect dose, unsatisfactory route of administration, and side effects. 
In a large dsd-LIFE clinical trial, in which 1040 adults with DSD participated, 20% of those 
receiving hormone replacement were dissatisfied with it, mostly due to adverse effects on 
mood [26, 27]. The authors suggest providing accurate information to patients about the use 
of this therapy, as well as individually adapting the course of therapy to the patient’s 
expectations. 
The number of DSD patients studied here is not large but is sufficient to preliminarily 
indicate some problems that are causes of psychic suffering. Their problems may be various 
in different ages, and so further monitoring of patients should be carried out. It is also 
necessary to confirm these observations on a larger group of patients in different age ranges. 
 
Conclusions 
The individuals with DSD and Y chromosome in the karyotype have increased risk of 
developing mental problems in comparison to the general Polish population. The risk factors 
seem to be: female gender, the lack of a vagina, the lack of virilisation (no enlarged clitoris), 
and no genital operations performed. In some cases, sex hormone replacement therapy may 
also pose a risk of mental problems. Particularly vulnerable groups are CAIS, PAIS, and 
CGD. Psychological support and an individual approach to the particular needs of these 
patients is necessary. 
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Table 1. Characteristics of the group of 59 patients with disorders of sex differentiation 
(DSD) 
Age (years) 
Minimum-maximum 
Median 
Mean ± SD 
16–65 
23.0 
26.1 ± 11.1 
Recorded sex (N) 
Women 
Men 
28 
31 
Diagnosis (N) Women Men 
15 
 
Complete gonadal dysgenesis (CGD) 
Partial gonadal dysgenesis (PGD) 
Asymmetric gonadal dysgenesis (AGD) 
Complete androgen insensitivity syndrome (CAIS) 
Partial androgen insensitivity syndrome (PAIS) 
Other (5-ARD, ovotestis) 
11 
0 
2 
2 
13 
0 
0 
12 
11 
0 
6 
2 
Clinical picture (N) Women Men 
Virilisation 
Without virilisation 
Vagina 
Without vagina 
Micropenis 
Normal penis 
Hypospadias 
Without hypospadias 
12  
16 
14 
14 
– 
– 
– 
– 
–  
- 
- 
- 
31 
0 
30 
1 
Treatment (N) Women Men 
Genital surgery 
Without genital surgery 
Hormonal substitution 
Without hormonal substitution 
6 
22 
26 
2 
29 
2 
10 
21 
N — number of subjects; CGD — complete gonadal dysgenesis; PGD — partial gonadal 
dysgenesis; AGD — asymmetric gonadal dysgenesis; CAIS — complete androgen 
insensitivity syndrome; PAIS — partial androgen insensitivity syndrome; 5-ARD — 5-alpha 
reductase deficiency; SD — standard deviation 
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Table 2. Mean raw scores obtained in the GHQ-28 test 
Group N 
Somatic 
symptoms 
Anxiety  
and 
insomnia 
Disorders  
of daily 
functioning 
Symptoms  
of 
depression 
General 
mental 
health status 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Total group 59 6.39 ± 3.7 5.88 ± 3.7 6.97 ± 2.3 2.8 ± 3.8 22.1 ± 9.9 
Recorded sex 
Women 28 7.4 ± 3.8a 7.3 ± 3.9b 7.5 ± 2.6 3.4 ± 3.6 25.6 ± 10.1b 
Men 31 5.5 ± 3.4a 4.6 ± 3.0b 6.5 ± 1.9 2.3 ± 4.1 18.8 ± 8.7b 
Diagnosis 
CGD 11 7.6 ± 3.7a 7.6 ± 4.0 6.5 ± 2.3 2.6 ± 2.3 24.2 ± 7.4 
PGD 12 5.3 ± 3.5a1 4.5 ± 3.7 6.2 ± 1.8 2.2 ± 4.7 18.1 ± 8.1 
AGD 13 4.4 ± 2.4a.a2.b 4.4 ± 2.6 6.6 ± 2.4 2.5 ± 3.9 17.9 ± 8.9 
CAIS 2 11.5 ± 9.2a1.b 7.5 ± 2.1 10.0 ± 1.4 10.5 ± 2.1 39.5 ± 14.9 
PAIS 19 7.0 ± 3.4a2 6.5 ± 4.1 7.7 ± 2.3 2.9 ± 3.6 24.3 ± 10.7 
Other  
(5-ARD, ovotestis) 
2 8.5 ± 3.5 7.0 ± 1.4 6.5 ± 0.7 1.0 23.0 ± 2.8 
Clinical picture 
Women  
with vagina 
14 7.2 ± 3.4 7.5 ± 3.7 6.6 ± 2.9 2.7 ± 2.3 24.0 ± 7.8 
Women  
without vagina 
14 7.6 ± 4.2 7.1 ± 4.2 8.4 ± 1.9a1 4.0 ± 4.5 27.2 ± 11.9a 
Women  
with virilisation 
12 6.1 ± 2.2 6.3 ± 3.9 7.8 ± 2.7a 2.8 ± 3.5 23.1 ± 8.8 
Women  
without virilisation 
16 8.4 ± 4.4 8.0 ± 3.9a 7.2 ± 2.6 3.8 ± 3.6 27.5 ± 10.8b 
Men  
with micropenis 
31 5.5 ± 3.4 4.6 ± 3.0a 6.5 ± 1.9a.a1 2.3 ± 4.0 18.8 ± 8.7a .b 
Men  
with hypospadias 
30 5.2 ± 3.3 4.6 ± 3.1 6.5 ± 1.9 2.3 ± 4.1 18.6 ± 8.8 
Treatment 
Genital surgery 35 5.4 ± 3.2a 5.2 ± 3.4 6.7 ± 2.3 2.7 ± 4.2 20.1 ± 9.6a 
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Without genital 
surgery 
24 7.8 ± 3.9
a 
6.9 ± 4.0 7.4 ± 2.2 2.9 ± 3.3 24.9 ± 9.8
a 
Hormonal 
substitution 
36 7.1 ± 3.7 6.5 ± 3.9 7.2 ± 2.4 2.7 ± 3.4 23.6 ± 10.0 
Without  
hormonal 
substitution 
23 5.4 ± 3.6 4.9 ± 3.2 6.6 ± 2.1 2.9 ± 4.5 19.6 ± 9.4 
a, a1, a2 — differences between averages of compared pairs (a-a, a1-a1, a2-a2) in individual 
groups significant at the level of p < 0.05; b — differences between the mean of compared 
pairs (b-b) in particular groups significant at p < 0.01 
N — number of subjects; CGD — complete gonadal dysgenesis; PGD — partial gonadal 
dysgenesis; AGD — asymmetric gonadal dysgenesis; CAIS — complete androgen 
insensitivity syndrome; PAIS — partial androgen insensitivity syndrome; 5-ARD — 5-alpha 
reductase deficiency; SD — standard deviation 
 
 
Table 3. Percentage distribution of disorders of sex differentiation (DSD) subjects with 
different levels of mental problems risk assessed by the GHQ-28 test scores converted to sten 
scores using the norms for the Polish adult population 
 
Group 
Low risk 
1–4 stens 
(%) 
Medium risk  
5–6 stens 
(%) 
High risk  
7–10 stens 
(%) 
Total group 30 46 24 
Recorded sex 
Women 29 50 21 
Men 32 42 26 
Diagnosis 
TGD 27 55 18 
PGD 33 42 25 
AGD 38 38 24 
CAIS 0 50 50 
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PAIS 32 47 21 
Other (5-ARD, ovotestis) 0 50 50 
Clinical picture 
Women with vagina 29 50 21 
Women without vagina  29 50 21 
Women with virilisation 33 50 17 
Women without virilisation 25 50 25 
Men with micropenis  3 42 26 
Men with hypospadias  33 43 24 
Treatment 
Genital surgery 34 40 26 
Without genital surgery 25 54 21 
Hormonal substitution 31 44 25 
Without hormonal 
substitution 
30 48 22 
TGD — total gonadal dysgenesis; CGD — complete gonadal dysgenesis; PGD — partial 
gonadal dysgenesis; AGD — asymmetric gonadal dysgenesis; CAIS — complete androgen 
insensitivity syndrome; PAIS — partial androgen insensitivity syndrome; 5-ARD — 5-alpha 
reductase deficiency 
 
